Magle Group Announces Publication of prospective HepaStar Trial Results Highlighting Promising Outcomes for DSM-TACE in Hepatocellular Carcinoma
07/01/2025
Magle PharmaCept as a part of Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) announces the publication of the final results of the prospective HepaStar trial, a multicenter observational trial evaluating the safety and effectiveness of EmboCept® S DSM 50 µm in the treatment of unresectable hepatocellular carcinoma (HCC).
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, with rising incidence and mortality rates. For patients with unresectable HCC, transarterial chemoembolization (TACE) is a widely used treatment option. The HepaStar study specifically focused on EmboCept® S DSM 50 µm, an innovative DSM-TACE technique based on Magle Group’s proprietary DSM (Degradable Starch Microsphere) technology.
Conducted at six European centers, the study provides crucial prospective insights into the use of DSM-TACE for patients with unresectable or recurrent HCC.
“DSM-TACE results in promising survival rates and low rates of treatment-related adverse events,” says PD Dr. med. Federico Collettini, senior attending physician at the renowned Charité – Universitätsmedizin Berlin, Germany and principal investigator of the HepaStar study.
This technique shows a favorable safety profile both in terms of treatment-related adverse events and liver function deterioration. The HepaStar study demonstrates that DSM-TACE achieves promising survival outcomes while maintaining a favorable safety profile, positioning it as an effective alternative to conventional TACE methods such as cTACE and DEB-TACE.
EmboCept® S DSM 50 µm is a CE-marked medical device approved for the treatment of liver and lung tumors. The publication of the HepaStar study marks another step in Magle Group’s commitment to expanding the therapeutic applications of its DSM®-based product portfolio.
